IO Biotech

Leadership team

Dr. Muhammad Al-Hajj Ph.D. (Chief Scientific Officer)

Dr. Mai-Britt Zocca Ph.D. (Founder, Pres, CEO, Principal Financial Officer & Director)

Dr. Eva Ehrnrooth M.D., Ph.D. (Chief Medical Officer)

Products/ Services

Biotechnology, Health Care, Therapeutics

Headquarters

Copenhagen, Hovedstaden, Denmark

Established

2014

Company Registration

SEC CIK number: 0001865494

URL

https://www.iobiotech.com

Overview

Location

Recognition and Award

References

Summary

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

History

IO Biotech was founded in 2016 by Eric Siu and Christina Lo, two biomedical engineers inspired to push the boundaries of medicine through innovative implantable medical technologies. Since then, IO Biotech has developed several implantable products including drug pumps and novel diagnostics for early-stage cancer detection.

Mission

IO Biotech strives to improve patient outcomes by designing and developing implantable medical technologies to advance personalized care.

Vision

IO Biotech aims to be a global leader in implantable medical technology, providing the best quality products backed by exceptional clinical outcomes.

Key Team

Prof. Inge Marie Svane M.D., Ph.D. (Founder & Clinical Advisor)

Prof. Mads Hald Andersen Ph.D. (Founder & Scientific Advisor)

Anders Ljungqvist (Founder)

Prof. Per Thor Straten (Founder)

Ms. Amy B. Sullivan (Chief Financial Officer)

Mr. Brian Burkavage (VP of Fin. & Chief Accounting Officer)

Mr. Mikkel Dybkjær (VP of Corp. Fin.)

Recognition and Awards

IO Biotech has been recognized by several industry awards, including the SBA Scientific and Research Innovative Company of the Year in 2018, and Fast Company's Most Innovative Companies award in 2020.